[
    [
        {
            "time": "2018-01-02",
            "original_text": "Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference",
            "features": {
                "keywords": [
                    "Lilly",
                    "Cantor Fitzgerald",
                    "healthcare",
                    "conference"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Animal Spirits for Elanco? Pet-Care Company’s Stock Is Well Positioned for Gains.",
            "features": {
                "keywords": [
                    "Elanco",
                    "pet-care",
                    "stock",
                    "gains"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Animal Spirits for Elanco? Pet-Care Company’s Stock Is Well Positioned for Gains.",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Antibody therapy developer AbCellera hires banks for U.S. IPO -sources",
            "features": {
                "keywords": [
                    "AbCellera",
                    "IPO",
                    "antibody therapy",
                    "hires banks"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Antibody therapy developer AbCellera hires banks for U.S. IPO -sources",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
            "features": {
                "keywords": [
                    "Lilly",
                    "Morgan Stanley",
                    "healthcare",
                    "conference"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly to Participate in Morgan Stanley Global Healthcare Conference",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "U.S. Drug Stocks Look Cheap. Here’s Why, According to One Analyst.",
            "features": {
                "keywords": [
                    "drug stocks",
                    "cheap",
                    "analyst"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "U.S. Drug Stocks Look Cheap. Here’s Why, According to One Analyst.",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "It’s Likely Too Late for Regeneron’s Virus Treatment",
            "features": {
                "keywords": [
                    "Regeneron",
                    "virus treatment",
                    "too late"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "It’s Likely Too Late for Regeneron’s Virus Treatment",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study",
            "features": {
                "keywords": [
                    "REYVOW",
                    "lasmiditan",
                    "migraine",
                    "Phase 3 study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]